NCT07777445Recruiting
Exercise Performance on Ambient Air vs. Low-Flow Liquid Oxygen Therapy in Pulmonary Vascular Disease (PVD)
Exercise Performance on Ambient Air vs. Commonly Prescribed Nasal Low Flow Oxygen Therapy in Patients With Exercise Induced Desaturation Due to Pulmonary Disease
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
The investigators aim to study the effect of liquid oxygen therapy (4l/min, nasal) )in Swiss residents with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 17 Aug 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Silvia Ulrich Somaini
- NCT number
- NCT07777445
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 1 Oct 2026 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \- Severe hypoxemia needing supplemental oxygen therapy defined as PaO2 \< 6.9 kPa
Other illness
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, walk disability etc.
Other
- Inability or contraindications to undergo the investigated intervention
Who the study is looking for
- \- Minimum 18 years of age
- Written informed consent
- Patients with diagnosed pulmonary arterial hypertension (PAH), distal chronic thromboembolic pulmonary hypertension (CTEPH), chronic obstructive pulmonary disease (COPD) with emphysema, COPD without emphysema, or interstitial lung disease
- Former desaturation under exercise defined as SpO2-decrease \>3%
- Treated with a stable drug therapy (with no changes for at least 14 days prior to screening)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Zurich Coordinator of this site? Confirm its status | Zurich | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.